As of 8:10 PM 06/17/13 All times are local (Market data is delayed by at least 15 minutes).
Executive Profile*
| Age | Total Calculated Compensation | This person is connected to 85 board members in 7 different organizations across 7 different industries.
See Board Relationships |
| 80 | --
|
Background*
Dr. Bertram Pitt, M.D., is a Scientific Advisor at Heart Failure at PeriCor Therapeutics, Inc. Dr. Pitt serves as Medical & Clinical Advisor at Synvista Therapeutics, Inc. He has been a Professor of Internal Medicine at the University of Michigan School of Medicine since 1977. He has been consulting companies like Warner Lambert Company, Beecham Pharmaceuticals, Nova Pharmaceuticals, Gensia Pharmaceuticals, Centocor Pharmaceuticals, Boots Pharmaceuticals, Ivax Pharmaceuticals, ... Pharmacia, Merck, Novartis, Takeda, Bristol Myers Squibb, and others. Dr. Pitt has been the Chairman or Co-chairman of a number of clinical trials in cardiology including: SOLVD; ELITE I and II; Prevent; Rales and Ephesus. Dr. Pitt is a Director at IVAX LLC since 2003. He serves as a Member of the Clinical Advisory Board at Relypsa, Inc. He serves as a Member of Scientific Advisory Board at Amorcyte Inc. and InVasc Therapeutics, Inc. He serves as a Member of Advisory Board at Aurasense LLC. Dr. Pitt is Member of the Editorial Board on a number of Journals in cardiovascular diseases. He is President of the Michigan Chapter of American College of Cardiology, and Chairman, Young Investigator's Award Committee of the American College of Cardiology. He distinguished himself as the Principal or Co-principal Investigator of a number of clinical trials, such as the Digitalis-Captopril Trial (300 patients), Studies of Left Ventricular Dysfunction (SOLVD - 6,700 patients), Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC Study - 600 patients), QUIET Study (1,750 patients), Prevent Trial (600 patients), Reflect II Trial (300 patients), RALES trial (3,200 patients), Ephesus (6,400 patients) and ELITE II (3,000 patients). Dr. Pitt is chairman of the steering committee of the NHLBI TOPCAT trial examining the effect of spironolactone in patients with HF and preserved LV systolic function; co-chairman of the Emphasis-HF trial examining the role of eplerenone in patients with NYHA Class II HF; chairman of Break-DHF; co-chairman of STOP-CKD; co-chairman of Exceed; co-chairman of Escape-SHF and Escape-DH F; chairman of a study evaluating the role of an aldostereone synthase inhibitor in patients with HF and is a member of the executive committee of the Accomplish trial. In addition, he serves as the chairman of the DSMB for the NHLBI HF-Action trial and has over 500 articles in peer reviewed journals. Dr. Pitt served as the Director of the Division of Cardiology at University of Michigan School of Medicine from 1977 to 1991 and the Associate Chairman for Academic and Industrial Programs from 1991 to 1999. He is a member of a number of medical organizations and has served as an advisor to the clinical trials branch of the NHLBI and a member of the FDA cardio-renal advisory board. He has published over 300 papers in his professional career. He is an acknowledged leader in the field of Cardiology and in pivotal international clinical trials. Dr. Pitt is also well-acknowledged by his consulting experiences with multiple pharmaceutical companies including: Pfizer, Takeda, Merck, Dai-Ichi Sankyo, Bayer, Boehringer-Ingelheim, Schering Plough and Astra Zeneca. He was the principal investigator in the landmark RALES study on heart failure and PLAC study on atherosclerosis. He has been awarded the James B. Herrick Award by the Council of Clinical Cardiology of the American Heart Association and has been elected to the Society of Scholars of the Johns Hopkins University. Dr. Pitt obtained his MD degree from the University of Basel in Switzerland in 1959. He subsequently did a fellowship in cardiology at the Johns Hopkins University School of Medicine and remained on the faculty there until 1977. He holds Ph.D. Dr. Pitt received his postdoctoral training at Beth Israel Hospital Boston and the Johns Hopkins Hospital University.
Corporate Headquarters*
221 West Grand Avenue
Montvale, New Jersey 07645
United States
Phone: 201-934-5000
Fax: 201-934-8880
Board Members Memberships*
2003-Present Director and Member of Compensation and Stock Incentive Committee
Education*
MD 1959 Universität Basel
Other Affiliations*
|
Annual Compensation*
There is no Annual Compensation data available.
Stock Options*
There is no Stock Options data available.
Total Compensation*
There is no Total Compensation data available.
|
*Data is at least as current as the most recent Definitive Proxy.
